The Genova Diagnostics Calprotectin gastrointestinal test is highly sensitive for evaluating inflammation within the gastrointestinal tract. The United States Food and Drug Administration (FDA) cleared calprotectin as a marker intended for differentiating Irritable Bowel Syndrome (IBS) from Inflammatory Bowel Disease (IBD). Calprotectin is the non-invasive gold standard for assessment of gastrointestinal inflammation – and as such, is a useful clinical tool for identifying patients who warrant further GI evaluation.
Fecal calprotectin is a simple, reliable, noninvasive marker that can be used as often as needed for the following clinical uses:
- Distinguishing between patients with Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) with a 99% Positive Predictive Value in patients with Rome Criteria and negative calprotectin (<50 ug/g)
- Determining disease activity and risk of relapse in IBD while assessing the level of mucosal healing
- Assisting in the selection of patients with abdominal symptoms who may require further diagnostic procedures
- Selecting patients for endoscopy as well as monitoring the response to treatment. This is especially useful for children, who may require general anesthesia to undergo more invasive analysis.
- Predicting relapse in patients with IBD, allowing an objective marker to decide when to treat
Calprotectin plays a regulatory role in the inflammatory process. It is released into the intestinal lumen during activation and cell death. Calprotectin comprises approximately 60% of the cytosolic protein in neutrophils, reflecting the flux of leukocytes into the intestinal lumen.
Emerging Studies on Calprotectin:
- Recent research highlights the role of calprotectin as an effective biomarker of mucosal healing
- Early trials indicate the value of calprotectin in correlating with endoscopy to predict relapse, define treatment response, and confirm clinical remission